A Phase 4 interventional study of Switch to DTG + FTC and Patient-centered monitoring in HIV-1-infection, Antiretroviral Therapy and Maintenance Therapy, sponsored by Calmy Alexandra. Completed at 7 sites in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-29.
Sponsored by Calmy Alexandra · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate whether maintenance antiretroviral therapy could be simplified to DTG + FTC dual therapy and/or patient-centered monitoring once virological suppression is achieved. Using a factorial design, the study aims to assess the efficacy of DTG + FTC dual therapy to maintain virological suppression through 48 weeks of follow-up as well as the costs of a patient-centered ART laboratory monitoring.
This is a pragmatic multicentre, 2x2 factorial randomized controlled trial with 1:1:1:1 randomization to switching to DTG-based maintenance dual therapy in association with FTC or continuation of cART, and to patient-centered monitoring or continuation of standard monitoring.
Patients will be followed during 48 weeks.
Calmy Alexandra is the lead sponsor of 7 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
On standard cART at the time of inclusion, i.e.:
Exclusion Criteria:
Previous ART change for unsatisfactory virological response, i.e. slow initial virological suppression, incomplete suppression or rebound. Change of drug or drug class for convenience or toxic effect prevention or management is allowed.
Note: patients with documented genotype(s) presenting only a M184V mutation remain eligible;
a. Presence of any INSTI-resistance. Non-availability of INSTI resistance testing is NOT an exclusion criteria.
b. Non availability of previous routine resistance test, at least for reverse transcriptase and protease genes.
Note: Subjects remain eligible in the absence of any previous resistance test only if they are on their antiretroviral regimen;
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients randomized to this arm will continue their current standard ART regimen (cART) and will continue a standard 3-monthly routine safety biological monitoring (including CD4 cell count, fasting lipids and glucose, renal and hepatic function tests) at their SHCS site.
Patients randomized to this arm will continue their current cART and will have immunological and safety blood examinations performed once per year and at least one options (decentralised venipuncture and blood tests, delivery of ARV drugs by mail and interview by phone or skype call) for weeks 6, 12 and 36
Other: Patient-centered monitoring
Patients randomized to this arm will be switched to DTG + FTC dual maintenance therapy and will have immunological and safety blood examinations performed once per year and at least one options (decentralised venipuncture and blood tests, delivery of ARV drugs by mail and interview by phone or skype call) for weeks 6, 12 and 36
Drug: Switch to DTG + FTC
Patients randomized to this arm will be switched to DTG + FTC dual maintenance therapy and will have immunological and safety blood examinations performed at screening and at week 48. In addition, patients will be ask to choose at least one of the following alternative options for weeks 6, 12 and 36: decentralised venipuncture and blood tests, delivery of ARV drugs by mail and Assessment and clinical interview by phone or skype call
Drug: Switch to DTG + FTC · Other: Patient-centered monitoring
Switch from standard cART to DTG + FTC dual maintenance therapy.
Immunological and safety blood examinations performed only once per year at least one options (decentralised venipuncture and blood tests, delivery of ARV drugs by mail and interview by phone or skype call) for weeks 6, 12 and 36
Efficacy of DTG-based maintenance therapy (< 100 copies/ml)
Proportion of patients maintaining HIV-RNA \<100 copies/ml throughout 48 weeks
Time frame: 48 weeks
Costs of a patient-centered ART monitoring
Direct costs of the two study arms from the health care system perspective at week 48
Time frame: 48 weeks
Efficacy of DTG-based maintenance therapy (<50 copies/ml)
Proportion of patients maintaining HIV-RNA \<50 copies/ml throughout 48 weeks
Time frame: 48 weeks
Efficacy of DTG-based therapy (<50 copies/ml) by FDA snapshot analysis
Proportion of patients with HIV-RNA \< 50 cp/ml at week 48
Time frame: 48 weeks
HIV-RNA >100 copies/ml as time to loss of virological response (TLOVR)
defined as the first of the two-confirmed HIV-RNA \>100 copies/ml (at least two weeks apart)
Time frame: 48 weeks
Change in CD4 cell count
from baseline to week 48
Time frame: 48 weeks
Change in HIV-DNA
from baseline to week 48
Time frame: 48 weeks
Change in lipidic profile
from baseline to week 48
Time frame: 48 weeks
Change in glucose profile
from baseline to week 48
Time frame: 48 weeks
Change in Framingham-calculated cardiovascular risk
from baseline to week 48
Time frame: 48 weeks
Change in glomerular function rate
from baseline to week 48
Time frame: 48 weeks
Proportion of patients with an adverse event
throughout week 48
Time frame: 48 weeks
Proportion of patients with a severe adverse event
throughout week 48
Time frame: 48 weeks
Proportion of patients with CNS adverse event
throughout week 48
Time frame: 48 weeks
Proportion of patients new to DTG with CNS symptoms
at 2 and 6 week
Time frame: 6 weeks
PROQOL questionnaire
from baseline to weeks 12 and 48
Time frame: 48 weeks
Patient's monitoring satisfaction for pts in the patient-centered monitoring arm
from baseline to weeks 24 and 48
Time frame: 48 weeks
Global satisfaction of the monitoring
at week 48
Time frame: 48 weeks
Proportion of patients in the patient-centered monitoring arm expressing willingness to change monitoring options
Monitoring satisfaction throughout 48 weeks
Time frame: 48 weeks
Patient's treatment satisfaction at week 48
at week 48
Time frame: 48 weeks
ARV treatment in the post study
ART decided to be used in the post study period
Time frame: 48 weeks
Study satisfaction
at week 48
Time frame: 48 weeks
Cost-effectiveness of study arms
at week 48
Time frame: 48 weeks
Change in patient weight
from baseline to week 48
Time frame: 48 weeks
Adherence questions
Patient adherence to treatment throughout 48 weeks of follow-up
Time frame: 48 weeks
Number of study-related extra clinical visits
performed outside trial scheduled throughout 48 weeks
Time frame: 48 weeks
Plan to share: No
Ran from May 2017 to primary completion in Apr 2018, 10 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Calmy Alexandra